Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Abstract Relapse is the main cause of treatment failure for leukaemia patients with unfavourable gene mutations who receive allogeneic haematopoietic stem cell transplantation (allo‐HSCT). There is no consensus on the indication of donor lymphocyte infusion (DLI) for prophylaxis of relapse after all...

Full description

Bibliographic Details
Main Authors: Rui Zhang, Lili Wang, Peng Chen, Xiaoning Gao, Shuhong Wang, Fei Li, Liping Dou, Chunji Gao, Yan Li, Daihong Liu
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Cancer Medicine
Subjects:
allogeneic peripheral blood stem cell transplantation
decitabine
donor lymphocyte infusion
relapse
unfavourable gene mutations
Online Access:https://doi.org/10.1002/cam4.3763

Internet

https://doi.org/10.1002/cam4.3763

Similar Items